Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2018 | Novel therapies in minimizing transplant complications

Mohamad Mohty • 18 Mar 2018
EBMT 2018
Hodgkin Lymphoma Brentuximab vedotin

The therapeutic landscape of Hodgkin lymphoma has improved considerably over the past 50 years, with patient outcomes improving due to accurate diagnoses. Here, Mohamad Mohty, MD, PhD, from Saint-Antoine Hospital, Paris, France, raises the issue that not all patients respond in the same way to therapy. Speaking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Prof. Mohty discusses the factors that may introduce complications in therapy response, and how novel therapies may hold the key in delivering tailored care to patients.

More from Mohamad Mohty

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:24
Comparing alloSCT outcomes in secondary and de-novo acute lymphoblastic leukemia
Mohamad Mohty • 15 Feb 2024
4:17
The evolving role of autoSCT in the age of CAR-T for multiple myeloma: current & future perspectives
Mohamad Mohty • 15 Feb 2024

Related Videos

2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:50
Results of the EuroNet-PHL-C1 trial: omission of radiotherapy in children and adolescents with cHL
Christine Mauz-Körholz • 8 Dec 2023
1:17
KEYNOTE-667: pembrolizumab plus COPDAC-28 for high-risk cHL with slow early response to OEPA
Christine Mauz-Körholz • 8 Dec 2023
0:52
Managing late effects of treatment in pediatric patients with Hodgkin lymphoma
Christine Mauz-Körholz • 8 Dec 2023
The content of VJHemOnc is intended for healthcare professionals